Throughout the ages, the crime/mystery genre has stayed marginally the same with a variety of tropes making their debut as time went on. Many of these tropes were introduced by notable writers, such as, Agatha Christie, Arthur Conan Doyle, Wilkie Collins, Patricia Highsmith, Dorothy L. Sayers, and others. Due to this, the researcher decided to pinpoint the most common or overexposed tropes within this genre and reinvent them within the narrative that the researcher has created. The tropes that will be utilized are the ones with a remote location and limited suspects, having every person connected to the victim to have a viable motive for murder, and the appearance of ordinary objects on or near the victim at the time of their murder that hold the answers to who did it. In the narrative, each trope will be taken and reimagined into a different context to create something new within the crime/mystery genre that has been seldom done before.

An adequate ADME/PK (absorption, distribution, metabolism, excretion, pharmacokinetics) profile is an essential quality for a drug. As part of the drug discovery process, leads are iteratively designed and optimized in order to simultaneously satisfy various properties such as appropriate ADME/PK levels and high biological activity for a target. The drug discovery process can be accelerated by improving the likelihood that a designed compound fulfils the necessary pharmacologic properties, and thus reducing the number of needed iterations. A promising technique is de novo drug design, where molecules are computationally generated based on a set of desired attributes. Our project aimed to benchmark the effectiveness of the ANDROMEDA ADME/PK conformal prediction models in guiding the generation of compounds toward an area of chemical space with good ADME/PK properties. For this, we used the REINVENT reinforcement learning framework built by the Molecular AI team at AstraZeneca. Here, we integrated 4 out the 14 available ANDROMEDA models (fabs , fdiss, CLint and Vss) as oracles in the scoring component of the generative model. Oral bioavailability (F) is a secondary parameter that was computed with the help of the aforementioned models and fu(unbound fraction in plasma), and serves as the fifth ADME/PK oracle in our analysis. We aimed to rediscover DRD2 bioactives with a good ADME/PK profile. Our results show that the ANDROMEDA models have a slight influence on the predicted ADME/PK properties of the generated compounds. The results do not show an increased likelihood of generating DRD2 ligands in the case of the primary ANDROMEDA models. However, when using the oral bioavailability oracle, the sampling likelihood increases for some of the approved DRD2 ligands. In conclusion, the oral bioavailability ANDROMEDA model can be a promising option for guiding the generation of novel compounds towards an area of chemical space with good ADME/PK properties.